D. W. Fry

发表

Tyrosine kinase inhibitors. 12. Synthesis and structure-activity relationships for 6-substituted 4-(phenylamino)pyrimido[5,4-d]pyrimidines designed as inhibitors of the epidermal growth factor receptor.

W. Denny, G. Rewcastle, A. Bridges, 1997, Journal of medicinal chemistry.

Tyrosine kinase inhibitors. 16. 6,5,6-tricyclic benzothieno[3, 2-d]pyrimidines and pyrimido[5,4-b-] and -[4,5-b]ĭndoles as potent inhibitors of the epidermal growth factor receptor tyrosine kinase.

A. Bridges, D. W. Fry, H. D. Showalter, 1999, Journal of medicinal chemistry.

Tyrosine kinase inhibitors. 13. Structure-activity relationships for soluble 7-substituted 4-[(3-bromophenyl)amino]pyrido[4,3-d]pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.

W. Denny, D. W. Fry, H. D. Showalter, 1997, Journal of medicinal chemistry.

Tyrosine kinase inhibitors. 7. 7-Amino-4-(phenylamino)- and 7-amino-4-[(phenylmethyl)amino]pyrido[4,3-d]pyrimidines: a new class of inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.

W. Denny, A. Bridges, D. W. Fry, 1995, Journal of medicinal chemistry.

Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor.

W. Denny, G. Rewcastle, A. Bridges, 1999, Journal of medicinal chemistry.

Tyrosine Kinase Inhibitors. Part 5. Synthesis and Structure‐Activity Relationships for 4‐((Phenylmethyl)amino)‐ and 4‐(Phenylamino) quinazolines as Potent Adenosine 5′‐Triphosphate Binding Site Inhibitors of the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor.

W. Denny, G. Rewcastle, A. Bridges, 1995 .

Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor.

W. Denny, G. Rewcastle, A. Bridges, 1996, Journal of medicinal chemistry.

Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.

W. Denny, G. Rewcastle, D. W. Fry, 1998, Journal of medicinal chemistry.

Tyrosine Kinase Inhibitors. Part 10. Isomeric 4‐((3‐Bromophenyl)amino) pyrido(d)pyrimidines are Potent ATP Binding Site Inhibitors of the Tyrosine Kinase Function of the Epidermal Growth Factor Receptor (EGFR) .

W. Denny, G. Rewcastle, A. Bridges, 1996 .

Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5'-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor.

W. Denny, G. Rewcastle, A. Bridges, 1995, Journal of medicinal chemistry.

2-Aminoquinazoline inhibitors of cyclin-dependent kinases.

D. W. Fry, E. Dobrusin, Y. Bathini, 2005, Bioorganic & medicinal chemistry letters.

Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.

N. Pryer, D. W. Fry, W. Elliott, 2004, Molecular cancer therapeutics.

Use of Artificial Intelligence and Machine Learning Algorithms with Gene Expression Profiling to Predict Recurrent Nonmuscle Invasive Urothelial Carcinoma of the Bladder.

Anirban P. Mitra, Richard J Cote, R. Cote, 2016, The Journal of urology.

The use of genetic programming in the analysis of quantitative gene expression profiles for identification of nodal status in bladder cancer

Anirban P. Mitra, R. Datar, R. Cote, 2006, BMC Cancer.

Isolation and characterization of glycolic acid dehydrogenase from human liver.

D. W. Fry, K. E. Richardson, 1979, Biochimica et biophysica acta.

A specific inhibitor of the epidermal growth factor receptor tyrosine kinase.

A. Bridges, D. W. Fry, A. McMichael, 1994, Science.

CI-1033, a pan-erbB tyrosine kinase inhibitor.

D. W. Fry, W. Elliott, W. Slichenmyer, 2001, Seminars in oncology.

Chapter 18. Protein Tyrosine Kinases and Cancer

D. W. Fry, E. Dobrusin, 1992 .

Site-directed irreversible inhibitors of the erbB family of receptor tyrosine kinases as novel chemotherapeutic agents for cancer.

D. W. Fry, David W. Fry, 2000, Anti-cancer drug design.

Cell Cycle and Biochemical Effects of PD 0183812

D. W. Fry, E. Dobrusin, W. Leopold, 2001, The Journal of Biological Chemistry.

Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6.

D. W. Fry, D. Mcnamara, Hairong Zhou, 2005, Journal of medicinal chemistry.

Cell Cycle and Biochemical Effects of PD 0183812 A POTENT INHIBITOR OF THE CYCLIN D-DEPENDENT KINASES CDK4 AND CDK6*

D. W. Fry, E. Dobrusin, W. Leopold, 2001 .

Enhanced polyglutamylation of aminopterin relative to methotrexate in the Ehrlich ascites tumor cell in vitro.

D. W. Fry, L. Matherly, I. Goldman, 1985, Cancer research.

Isolation and characterization of glycolic acid oxidase from human liver.

D. W. Fry, K. E. Richardson, David W. Fry, 1979, Biochimica et biophysica acta.

Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors.

P. Ellis, W. Denny, A. Bridges, 2006, Journal of medicinal chemistry.

Transport of the antitumor antibiotic Cl-920 into L1210 leukemia cells by the reduced folate carrier system.

D. W. Fry, T. Boritzki, J. Besserer, 1984, Cancer research.

Effects of 2 , 4-Dinitrophenol and Other Metabolic Inhibitors on the Bidirectional Carrier Fluxes , Net Transport , and Intracellular Binding of Methotrexate in Ehrlich Ascites Tumor Cells 1

J. White, D. W. Fry, I. Goldman, 2006 .

Further studies on the charge-related alterations of methotrexate transport in Ehrlich ascites tumor cells by ionic liposomes: Correlation with liposome-cell association

D. W. Fry, I. Goldman, 1982, The Journal of Membrane Biology.

Expression, purification and characterization of focal adhesion kinase using a baculovirus system.

D. W. Fry, P. Keller, B. E. Withers, 1996, Protein expression and purification.

Design of a potent peptide inhibitor of the epidermal growth factor receptor tyrosine kinase utilizing sequences based on the natural phosphorylation sites of phospholipase C-γ1

Juswinder Singh, D. W. Fry, A. McMichael, 1994, Peptides.

Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor.

W. Denny, A. Doherty, A. Bridges, 1998, Proceedings of the National Academy of Sciences of the United States of America.

Membrane transport alterations as a mechanism of resistance to anticancer agents.

D. W. Fry, R. Jackson, 1986, Cancer surveys.

Pyrido[2,3-d]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4.

D. W. Fry, W. Elliott, D. Mcnamara, 2005, Journal of medicinal chemistry.

Biochemical and antitumor activity of tiazofurin and its selenium analog (2-beta-D-ribofuranosyl-4-selenazolecarboxamide).

D. W. Fry, W. Leopold, R. Jackson, 1985, Biochemical pharmacology.

Isolation, purification, and partial characterization of formate dehydrogenase from soybean seed.

D. W. Fry, K. E. Richardson, M. P. Farinelli, 1983, Plant physiology.

Inhibition of type II topoisomerase by fostriecin.

D. W. Fry, R. Jackson, T. Boritzki, 1988, Biochemical pharmacology.

The biochemical pharmacology of CI-920, a structurally novel antibiotic with antileukemic activity.

D. W. Fry, B. J. Roberts, W. Leopold, 1985, Advances in Enzyme Regulation.

Rapid separation of low molecular weight solutes from liposomes without dilution.

J. White, D. W. Fry, I. Goldman, 1978, Analytical biochemistry.

Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family

T. Myers, E. Liu, S. Bates, 2002, Oncogene.

Inhibitors of tyrosine kinase

D. W. Fry, A. Kraker, W. Klohs, 1997, Current opinion in oncology.

Akt, MAPK (Erk1/2), and p38 Act in Concert to Promote Apoptosis in Response to ErbB Receptor Family Inhibition*

D. W. Fry, J. Nelson, 2001, The Journal of Biological Chemistry.

Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor.

W. Denny, G. Rewcastle, A. Bridges, 1996, Journal of medicinal chemistry.

Potent inhibition of thymidylate synthase by two series of nonclassical quinazolines.

D. W. Fry, D. Mcnamara, L. M. Werbel, 1990, Journal of medicinal chemistry.

Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors.

A. Doherty, D. W. Fry, H. D. Showalter, 1997, Journal of medicinal chemistry.

Discovery and structure-activity studies of a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors

A. Doherty, D. W. Fry, J. M. Hamby, 1997 .

Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.

W. Denny, G. Rewcastle, A. Bridges, 1996, Journal of medicinal chemistry.

Biological and biochemical properties of new anticancer folate antagonists

D. W. Fry, R. Jackson, 2004, Cancer and Metastasis Reviews.

Inhibition of human 5-phosphoribosyl-1-pyrophosphate synthetase by 4-amino-8-(beta-D-ribofuranosylamino)-pyrimido[5,4-d]pyrimidine-5'- monophosphate: evidence for interaction at the ADP allosteric site.

D. W. Fry, R. Switzer, M. Becker, 1995, Molecular pharmacology.

Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrolo- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: synthesis, biological evaluation, and modeling of the mode of binding.

W. Denny, D. W. Fry, H. D. Showalter, 1997, Journal of medicinal chemistry.

STRUCTURE‐ACTIVITY RELATIONSHIPS FOR 4‐ANILINOQUINAZOLINES AS POTENT INHIBITORS AT THE ATP BINDING SITE OF THE EPIDERMAL GROWTH FACTOR RECEPTOR IN VITRO

W. Denny, G. Rewcastle, A. Bridges, 1996, Clinical and experimental pharmacology & physiology.

Tyrosine Kinase Inhibitors. 14. Structure−Activity Relationships for Methyl- amino-Substituted Derivatives of 4-[(3-Bromophenyl)amino]-6-(methylamino)- pyrido[3,4-d]pyrimidine (PD 158780), a Potent and Specific Inhibitor of the Tyrosine Kinase Activity of Receptors for the EGF Family of Growth Facto

W. Denny, G. Rewcastle, D. W. Fry, 1998 .

Potent inhibition of thymidylate synthase by two series of nonclassical quinazolines.

D. W. Fry, D. Mcnamara, L. M. Werbel, 1990, Journal of medicinal chemistry.

Design, biochemical pharmacology, electrochemistry and tumour biology of anti-tumour anthrapyrazoles.

D. W. Fry, W. Leopold, J. Lown,, 1986, Anti-cancer drug design.

In vitro DNA strand scission and inhibition of nucleic acid synthesis in L1210 leukemia cells by a new class of DNA complexers, the anthra[1,9-cd]pyrazol-6(2H)-ones (anthrapyrazoles).

D. W. Fry, R. Jackson, T. Boritzki, 1985, Biochemical pharmacology.

Biochemical pharmacology of anthracenediones and anthrapyrazoles.

D. W. Fry, David W. Fry, 1991, Pharmacology & therapeutics.

Inhibitors of protein tyrosine kinases.

A. Bridges, D. W. Fry, 1995, Current opinion in biotechnology.

K+-induced alterations of energetics and exchange diffusion in the carrier-mediated transport of the folic acid analog, methotrexate, in Ehrlich ascites tumor cells.

D. W. Fry, I. Goldman, R. Cybulski, 1980, Biochimica et biophysica acta.

Basically substituted ellipticine analogues as potential antitumor agents.

D. W. Fry, D. Worth, L. M. Werbel, 1986, Journal of Medicinal Chemistry.

Teniposide (VM-26)- and etoposide (VP-16-213)-induced augmentation of methotrexate transport and polyglutamylation in Ehrlich ascites tumor cells in vitro.

D. W. Fry, I. Goldman, J. Yalowich, 1982, Cancer research.

Analysis of the role of membrane transport and polyglutamation of methotrexate in gut and the Ehrlich tumor in vivo as factors in drug sensitivity and selectivity.

D. W. Fry, I. Goldman, L. A. Anderson, 1983, Cancer research.

A BRIEF HISTORY OF CANCER CHEMOTHERAPY

Takashi Tsuruo, David J. Kerr, Qiang Yu, 2002 .

Inosine 5’-Phosphate Dehydrogenase as a Target for Cancer Chemotherapy. Results with 3-Deazaguanine, Tiazofurin and 2-β-D-Ribofuranosylselenazole-4-Carboxamide (PD-111232)

D. W. Fry, R. Jackson, T. Boritzki, 1984 .

Role of methotrexate polyglutamylation and cellular energy metabolism in inhibition of methotrexate binding to dihydrofolate reductase by 5-formyltetrahydrofolate in Ehrlich ascites tumor cells in vitro.

D. W. Fry, L. Matherly, I. Goldman, 1983, Cancer research.

Dezaguanine mesylate: a new antipurine antimetabolite

D. W. Fry, W. Leopold, R. Jackson, 2004, Investigational New Drugs.

Cytotoxic synergism between trimetrexate and etoposide. Evidence that trimetrexate potentiates etoposide-induced protein-associated DNA strand breaks in L1210 leukemia cells through alterations in intracellular ATP concentrations.

D. W. Fry, 1990, Biochemical pharmacology.

Biochemical pharmacology and antitumor properties of

D. W. Fry, W. Leopold, R. Jackson, 1989 .

Approaches to the measurement of intracellular adenine and the discrimination between adenine transport and metabolism in L1210 leukemia cells.

D. W. Fry, I. Goldman, R. Cybulski, 1982, Biochimica et biophysica acta.

Biochemical pharmacology and experimental chemotherapy studies with guanine-7-oxide, a novel purine antibiotic.

D. W. Fry, W. Leopold, R. Jackson, 1987, Advances in enzyme regulation.

Plasma vascular endothelial growth factor and interleukin-8 as biomarkers of antitumor efficacy of a prototypical erbB family tyrosine kinase inhibitor.

J. Christensen, D. W. Fry, W. Elliott, 2005, Molecular cancer therapeutics.

Pharmacologic inhibition of cyclin-dependent kinase 4/6 activity arrests proliferation in myoblasts and rhabdomyosarcoma-derived cells

P. Houghton, D. W. Fry, S. Skapek, 2006, Molecular Cancer Therapeutics.

Induced Focal Adhesion Kinase (FAK) Expression in FAK-Null Cells Enhances Cell Spreading and Migration Requiring Both Auto- and Activation Loop Phosphorylation Sites and Inhibits Adhesion-Dependent Tyrosine Phosphorylation of Pyk2

S. Hanks, D. W. Fry, P. Ruest, 1999, Molecular and Cellular Biology.

Protein tyrosine kinases as therapeutic targets in cancer chemotherapy and recent advances in the development of new inhibitors

David W. Fry, D. W. Fry, 1994 .

Role of Tyrosine Kinase Activity of Epidermal Growth Factor Receptor in the Lysophosphatidic Acid-stimulated Mitogen-activated Protein Kinase Pathway*

J. Turkson, R. Jove, Jie Wu, 1998, The Journal of Biological Chemistry.

Generation and external validation of a tumor-derived 5-gene prognostic signature for recurrence of lymph node-negative, invasive colorectal carcinoma

D. W. Fry, L. Boardman, A. Almal, 2012, Cancer.

Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinases.

A Whitty, A. Whitty, D. W. Fry, 1997, Journal of medicinal chemistry.

Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors.

D. W. Fry, David W. Fry, 1999 .

CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer.

D. W. Fry, L. F. Allen, P. Lenehan, 2003, Seminars in oncology.

Anticancer therapy targeting the erbB family of receptor tyrosine kinases.

D. W. Fry, W. Slichenmyer, William J Slichenmyer, 2001, Seminars in oncology.

CHAPTER 3 – GROWTH FACTOR AND SIGNAL TRANSDUCTION TARGETS FOR CANCER THERAPY

A. Bridges, D. W. Fry, A. Kraker, 2002 .

Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor

P. Ellis, A. Bridges, D. W. Fry, 2008, Molecular Cancer Therapeutics.

Enantioselective inhibition of the epidermal growth factor receptor tyrosine kinase by 4-(alpha-phenethylamino)quinazolines.

A. Bridges, D. W. Fry, H. Zhou, 1995, Bioorganic & medicinal chemistry.

Rapid formation of poly-gamma-glutamyl derivatives of methotrexate and their association with dihydrofolate reductase as assessed by high pressure liquid chromatography in the Ehrlich ascites tumor cell in vitro.

D. W. Fry, D. Goldman, I. Goldman, 1982, The Journal of biological chemistry.

Adenosine stimulation of uphill adenine transport in L1210 leukemia cells. Evidence for a novel countertransport mechanism.

D. W. Fry, I. Goldman, R. Cybulski, 1981, The Journal of biological chemistry.

Biochemical and antiproliferative properties of 4-[ar(alk)ylamino]pyridopyrimidines, a new chemical class of potent and specific epidermal growth factor receptor tyrosine kinase inhibitor.

W. Denny, G. Rewcastle, A. Bridges, 1997, Biochemical pharmacology.

Chapter 16. Recent Advances in Tyrosine Kinase Inhibitors

D. W. Fry, 1996 .

Inhibition of epidermal growth factor receptor tyrosine kinase fails to suppress adenoma formation in ApcMin mice but induces duodenal injury.

W. Karnes, L. Burgart, A. Bridges, 2000, Cancer research.

Differential utilization and localization of ErbB receptor tyrosine kinases in skin compared to normal and malignant keratinocytes.

James T. Elder, E. Wagner, R. Derynck, 2001, Neoplasia.

PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner.

J. Baselga, J. Albanell, D. W. Fry, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Strategies for the discovery of novel tyrosine kinase inhibitors with anticancer activity.

D. W. Fry, H. D. Showalter, W. Elliott, 1994, Anti-cancer drug design.

Biochemical pharmacology of the lipophilic antifolate, trimetrexate.

D. W. Fry, W. Leopold, R. Jackson, 1984, Advances in enzyme regulation.

Studies on the biochemical mechanism of the novel antitumor agent, CI-920

D. W. Fry, R. Jackson, T. Boritzki, 2004, Cancer Chemotherapy and Pharmacology.

Using genetic programming to classify node positive patients in bladder cancer

Arpit A. Almal, William P. Worzel, Richard J. Cote, 2006, GECCO.

Drug‐induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy

A. Citri, Y. Yarden, L. Neckers, 2002, The EMBO journal.

Cross resistance of pleiotropically drug resistant P338 leukemia cells to the lipophilic antifolates trimetrexate and BW 301U.

D. W. Fry, W. Klohs, J. Besserer, 1986, Cancer letters.

G1 cell cycle arrest due to the inhibition of erbB family receptor tyrosine kinases does not require the retinoblastoma protein.

D. W. Fry, A. Gonzales, 2004, Experimental cell research.

Biological and biochemical activities of the novel antitumor antibiotic PD 114,759 and related derivatives

D. W. Fry, W. Leopold, J. Shillis, 2004, Investigational New Drugs.

Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer.

D. W. Fry, W. Elliott, L. F. Allen, 2002, Seminars in oncology.

Augmentation of the intracellular levels of polyglutamyl derivatives of methotrexate by vincristine and probenecid in Ehrlich ascites tumor cells.

D. W. Fry, I. Goldman, J. Yalowich, 1982, Cancer research.

Effects of 2,4-dinitrophenol and other metabolic inhibitors on the bidirectional carrier fluxes, net transport, and intracellular binding of methotrexate in Ehrlich ascites tumor cells.

J. White, D. W. Fry, I. Goldman, 1980, Cancer research.

Biochemical pharmacology and DNA-drug interactions by Cl-958, a new antitumor intercalator derived from a series of substituted 2H-[1]benzothiopyrano[4,3,2-cd]indazoles.

D. W. Fry, J. Besserer, 1988, Molecular pharmacology.

Preclinical studies with trimetrexate: a review of conclusions and unanswered questions.

D. W. Fry, W. Leopold, R. Jackson, 1988, Seminars in oncology.

Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2'-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congeners.

W. Denny, D. W. Fry, H. D. Showalter, 1997, Journal of medicinal chemistry.

Relationship between membrane transport of methotrexate and endogenous cyclic adenosine 3':5'-monophosphate in the Ehrlich ascites tumor.

J. White, R. Carchman, D. W. Fry, 1980, Cancer research.

Cytotoxic synergism between trimetrexate and etoposide in l1210 cells trimetrexate mediated potentiation of the protein associated dna strand breaks produced by etoposide

D. W. Fry, 1988 .

Alterations of the carrier-mediated transport of an anionic solute, methotrexate, by charged liposomes in Ehrlich ascites tumor cells

J. White, D. W. Fry, I. Goldman, 1979, The Journal of Membrane Biology.

Characterization of trimetrexate transport in human lymphoblastoid cells and development of impaired influx as a mechanism of resistance to lipophilic antifolates.

D. W. Fry, J. Besserer, 1988, Cancer research.

Phosphorylated fragments of the epidermal growth factor receptor: Sequence specificity for binding to phospholipase Cγ1 SH2 domains, and for kinase and phosphatase activity

J. Dixon, D. W. Fry, A. McMichael, 1994 .

2-Aminoquinazoline inhibitors of cyclin-dependent kinases.

D. W. Fry, E. Dobrusin, Y. Bathini, 2005, Bioorganic & medicinal chemistry letters.

Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenografts

A. Bridges, D. W. Fry, W. Elliott, 2000, Cancer Chemotherapy and Pharmacology.

In vivo and in vitro evaluation of the alkylating agent carmethizole.

D. W. Fry, W. Elliott, W. Leopold, 1991, Cancer research.

Characteristics of the accumulation of methotrexate polyglutamate derivatives in Ehrlich ascites tumor cells and isolated rat hepatocytes.

D. W. Fry, D. Gewirtz, I. Goldman, 1983, Advances in experimental medicine and biology.

Cytoskeletal and morphological changes associated with the specific suppression of the epidermal growth factor receptor tyrosine kinase activity in A431 human epidermoid carcinoma.

D. W. Fry, J. Nelson, 1997, Experimental cell research.

Inhibition of 5-phosphoribosyl-1-pyrophosphate synthetase by the monophosphate metabolite of 4-amino-8-(beta-D-ribofuranosylamino)pyrimido[5,4-d]pyrimidine: a novel mechanism for antitumor activity.

D. W. Fry, W. Leopold, R. Jackson, 1993, Molecular pharmacology.

Tyrosine kinase inhibitors. 4. Structure-activity relationships among N- and 3-substituted 2,2'-dithiobis(1H-indoles) for in vitro inhibition of receptor and nonreceptor protein tyrosine kinases.

W. Denny, G. Rewcastle, D. W. Fry, 1995, Journal of medicinal chemistry.

Inhibition of basic fibroblast growth factor-mediated tyrosine phosphorylation and protein synthesis by PD 145709, a member of the 2-thioindole class of tyrosine kinase inhibitors.

D. W. Fry, J. Nelson, 1995, Anti-cancer drug design.

Correlations between the expression, phosphotyrosine content and enzymatic activity of focal adhesion kinase, pp125FAK, in tumor and nontransformed cells.

S. Hanks, D. W. Fry, B. E. Withers, 1996, Cancer biochemistry biophysics.

Mechanism of action of erbB tyrosine kinase inhibitors.

D. W. Fry, 2003, Experimental cell research.

Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases.

D. Boschelli, D. W. Fry, S. Trumpp-Kallmeyer, 2000, Journal of medicinal chemistry.

Tyrosine kinase inhibitors. 1. Structure-activity relationships for inhibition of epidermal growth factor receptor tyrosine kinase activity by 2,3-dihydro-2-thioxo-1H-indole-3-alkanoic acids and 2,2'-dithiobis(1H-indole-3-alkanoic acids).

W. Denny, G. Rewcastle, D. W. Fry, 1993, Journal of Medicinal Chemistry.

Use of Artificial Intelligence and Machine Learning Algorithms with Gene Expression Profiling to Predict Recurrent Nonmuscle Invasive Urothelial Carcinoma of the Bladder.

Anirban P. Mitra, R. Cote, D. W. Fry, 2016, The Journal of urology.

Growth inhibition of nasopharyngeal carcinoma cells by EGF receptor tyrosine kinase inhibitors.

D. W. Fry, W. Elliott, P. Vincent, 1999, Anticancer research.